Chemistry:Etaracizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | alpha-v beta-3 integrin |
| Clinical data | |
| Trade names | Abegrin |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6392H9908N1732O1996S42 |
| Molar mass | 144302.22 g·mol−1 |
  (what is this?) (verify) | |
Etaracizumab, also known as MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,[1] ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]
It is an enhanced iteration of Vitaxin, also known as MEDI-523. Both are derived from the mouse antibody LM609.[4]
References
- ↑ 1.0 1.1 "Etaracizumab". Statement On A Nonproprietary Name Adopted By The Usan Council. http://www.ama-assn.org/ama1/pub/upload/mm/365/etaracizumab.pdf.
- ↑ "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia 10 (11): 1259–67. November 2008. doi:10.1593/neo.08740. PMID 18953435.
- ↑ "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational New Drugs 26 (1): 35–43. February 2008. doi:10.1007/s10637-007-9077-0. PMID 17876527.
- ↑ "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research 11 (21): 7851–60. November 2005. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.
 |  |
